Adenosine Receptors As Promising Therapeutic Targets for Drug Development in Chronic Airway Inflammation

Title: Adenosine Receptors As Promising Therapeutic Targets for Drug Development in Chronic Airway Inflammation

Volume: 7 Issue: 6

Author(s): Riccardo Polosa and Stephen T. Holgate

Affiliation:

Keywords: adenosine, adenosine receptors, inflammation, asthma, COPD

Abstract: A growing body of evidence has emerged in support of a pro-inflammatory role for adenosine in the pathogenic mechanisms of chronic inflammatory disorders of the airways such as asthma and COPD. The demonstration that adenosine enhances mast cell allergen-dependent activation, the notion that elevated levels of adenosine are present in chronically inflamed airways, and the results from exposure studies of nebulised adenosine showing dose-dependent bronchoconstriction in subjects with asthma and COPD, emphasise the importance of adenosine in the initiation, persistence and progression in these common inflammatory disorders of the airways. Adenosine exerts its manifold biological activities by interacting with at least four adenosine receptor subtypes. Selective activation or blockade of these sites is being exploited by the pharmaceutical industry in an attempt to generate novel therapies for asthma and COPD. This review article intends to address the potential role of adenosine in asthma and to put forward the idea that drugs that have been developed to selectively activate or downregulate adenosine receptor subtypes may constitute a considerable advance in the management of chronic airway inflammation.

Cite this article as:

Polosa Riccardo and Holgate T. Stephen, Adenosine Receptors As Promising Therapeutic Targets for Drug Development in Chronic Airway Inflammation, Current Drug Targets 2006; 7 (6) . https://dx.doi.org/10.2174/138945006777435236